In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Abstract Profiling the T-Cell Receptor (TCR) repertoire is establishing as a potent approach
to investigate autologous and treatment-induced antitumor immune response. Technical and …

Immune checkpoint inhibitors have reshaped the prognostic of several tumor types,
including metastatic colorectal tumors with microsatellite instability (MSI). However, 90-95 …

Simple Summary Between 5% and 15% of colorectal cancers (CRC) show deficiencies in
the mismatch repair machinery and high microsatellite instability (dMMR/MSI-H). dMMR/MSI …

Precision medicine has transformed the way urothelial carcinoma is managed. However,
current practices are limited by the availability of tissue samples for genomic profiling and …

Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd),
often respond to immune checkpoint blockade therapies, while those with mismatch repair …

Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Purpose: Current glioma diagnostic guidelines call for molecular profiling to stratify patients
into prognostic and treatment subgroups. In case the tumor tissue is inaccessible …

Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have
revealed divergent longitudinal trajectories in gliomas, but early molecular features steering …

Abstract Background. The DNA Mismatch repair (MMR) system is a highly preserved protein
complex recognizing short insertions, short deletions and single base mismatches during …